Transformative Psychopharmacology: the Case of 5-Methoxy-N,N-Dimethyltryptamine
Jan M Keppel Hesselink | International Journal of Psychotherapy Practice and Research | 2 January 2019
How do psychedelics work?
Carhart-Harris, R. L. | Current opinion in psychiatry | 1 January 2019
DARK Classics in Chemical Neuroscience: Atropine, Scopolamine, and Other Anticholinergic Deliriant Hallucinogens
Lakstygal, A., Kolesnikova, T., Khatsko, S., Zabegalov, K., Volgin, A., Demin, K., & Kalueff, A. | ACS chemical neuroscience | 19 December 2018
A Jamesian Response to Reductionism in the Neuropsychology of Religious Experience
Kime, K. G., & Snarey, J. R. | Archive for the Psychology of Religion | 13 December 2018
Self-Experiments with Psychoactive Substances: A Historical Perspective
Passie, T., & Brandt, S. D. | Handbook of Experimental Pharmacology | 27 November 2018
A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder
Barsuglia, J. P., Polanco, M., Palmer, R., Malcolm, B. J., Kelmendi, B., & Calvey, T. | Progress in brain research | 25 October 2018
Kappa Opioid Receptor Agonist Mesyl Sal B Attenuates Behavioral Sensitization to Cocaine with Fewer Aversive Side-Effects than Salvinorin A in Rodents.
Kivell, B., Paton, K., Kumar, N., Morani, A., Culverhouse, A., Shepherd, A., ... & Prisinzano, T. | Molecules | 11 October 2018
Increased use of illicit drugs in a Dutch cluster headache population
de Coo, I. F., Naber, W. C., Wilbrink, L. A., Haan, J., Ferrari, M. D., & Fronczek, R. | Cephalalgia | 5 October 2018
Whole-Brain Multimodal Neuroimaging Model Using Serotonin Receptor Maps Explains Non-linear Functional Effects of LSD
Deco, G., Cruzat, J., Cabral, J., Knudsen, G. M., Carhart-Harris, R. L., Whybrow, P. C., & Kringelbach, M. L. | Current biology | 27 September 2018
Understanding Central Nervous System Effects of Deliriant Hallucinogenic Drugs through Experimental Animal Models
Volgin, A. D., Yakovlev, O. A., Demin, K. A., Alekseeva, P. A., Kyzar, E. J., Collins, C., ... & Kalueff, A. V. | ACS chemical neuroscience | 25 September 2018
Psychoplastogens: A Promising Class of Plasticity-Promoting Neurotherapeutics
Olson, D. E. | Journal of experimental neuroscience | 19 September 2018
Psychedelics and psychotherapy in Canada: Humphry Osmond and Aldous Huxley.
Dyck, E., & Farrell, P. | History of psychology | August 2018
The epidemiology of 5-methoxy- N,N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption
Davis, A. K., Barsuglia, J. P., Lancelotta, R., Grant, R. M., & Renn, E. | Journal of Psychopharmacology | 30 April 2018
The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption
Davis, A. K., Barsuglia, J. P., Lancelotta, R., Grant, R. M., & Renn, E. | Journal of Psychopharmacology | 30 April 2018
Acute pharmacological effects of 2C-B in humans: An observational study
Papaseit, E., Farré, M., Perez-Maña, C., Torrens, M., Ventura, M., Pujadas, M., ... & González, D. | Frontiers in Pharmacology | 13 March 2018
Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats
Elmore, J. S., Decker, A. M., Sulima, A., Rice, K. C., Partilla, J. S., Blough, B. E., & Baumann, M. H. | Neuropharmacology | 1 March 2018
Tolerance and Tachyphylaxis to Head Twitches Induced by the 5-HT2A Agonist 25CN-NBOH in Mice
Buchborn, T., Lyons, T., & Knöpfel, T. | Frontiers in Pharmacology | 6 Februari 2018
The experience elicited by hallucinogens presents the highest similarity to dreaming within a large database of psychoactive substance reports
Tagliazucchi, E., & Sanz, C. | Frontiers in Neuroscience | 4 January 2018
Novel psychotherapeutics – a cautiously optimistic focus on Hallucinogens
Sherwood, A. M., & Prisinzano, T. E. | Expert Review of Clinical Pharmacology | 17 December 2017
The serotonin hallucinogen 5-MeO-DMT alters cortico-thalamic activity in freely moving mice: Regionally-selective involvement of 5-HT1A and 5-HT2A receptors
Riga, M. S., Lladó-Pelfort, L., Artigas, F., & Celada, P. | Neuropharmacology | 6 December 2017
A regulatory perspective on the evaluation of hallucinogen drugs for human use
Calderon, S. N., Hunt, J., & Klein, M. | Neuropharmacology | 24 November 2017
The ‘Endless Trip’: Psychopathology and Psychopharmacology in the Hallucinogen Persisting Perception Disorder/HPPD and the NPS. A systematic review
Orsolini, L., Papanti, G. D., De Berardis, D., Guirguis, A., Corkery, J. M., & Schifano, F. | Frontiers in Psychiatry | 20 November 2017
Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences
Carbonaro, T. M., Johnson, M. W., Hurwitz, E., & Griffiths, R. R. | Psychopharmacology | 7 November 2017
Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT
Dakic, V., Nascimento, J. M., Sartore, R. C., de Moraes Maciel, R., Araujo, D. B., Ribeiro, S., ... & Rehen, S. K. | Scientific Reports | 9 October 2017
The Mechanisms of Psychedelic Visionary Experiences: Hypotheses from Evolutionary Psychology
Winkelman, M. J. | Frontiers in Neuroscience | 28 September 2017